Evaluation of cardiovascular risk indices in type II diabetes mellitus

2015 ◽  
Vol 2 (2) ◽  
pp. 39-43
Author(s):  
ME Adu ◽  
HA Ukwamedu ◽  
ES Oghagbon
2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Marouane Boukhris ◽  
Salvatore Davide Tomasello ◽  
Francesco Marzà ◽  
Sonia Bregante ◽  
Francesca Romana Pluchinotta ◽  
...  

Coronary heart disease is the main cause of death in postmenopausal women (PMW); moreover its mortality exceeds those for breast cancer in women at all ages. Type II diabetes mellitus is a major cardiovascular risk factor and there is some evidence that the risk conferred by diabetes is greater in women than in men. It was established that the deficiency of endogenous estrogens promotes the atherosclerosis process. However, the impact of estrogen replacement therapy (ERT) on cardiovascular prevention remains controversial. Some authors strongly recommend it, whereas others revealed a concerning trend toward harm. This review tries to underlines the different components of cardiovascular risk in diabetic PMW and to define the place of ERT.


2021 ◽  
Vol 17 (3) ◽  
pp. 475-485 ◽  
Author(s):  
Ez Alddin Rajjoub Al-Mahdi ◽  
Vivencio Barrios ◽  
Jose L Zamorano

Type II diabetes mellitus is a known cardiovascular risk factor and its prevalence continues to increase. A revolution in the Type II diabetes mellitus treatment has occurred with the arrival of new antidiabetic drugs, which are thought to compromise metformin place. We aim to review the pharmacology, available evidence and clinical aspects of metformin use in the era of new antidiabetics.


Sign in / Sign up

Export Citation Format

Share Document